Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

QLT INC T.QLT

"QLT Inc is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians."


TSX:QLT - Post by User

Bullboard Posts
Comment by sometoaston Dec 23, 2004 1:28pm
215 Views
Post# 8353285

RE: Price for treatment

RE: Price for treatmentApparently, this is the pricing breakdown: Macugen is about $1000-1300 per injection and 18 treatments are needed over 2 years (total cost for Macugen treatment could range from $18 to 23 K) Visudyne is $1300-2000 per injection and 5 treatments are needed over 2 years (total cost for Visudyne might be $6 to 10 K). In addition to the substantial cost savings, there are far fewer trips to the doctor and less invasive treatment (needle in the arm for V vs needle in the eye for Macugen). On the other hand, Macugen does seem to work quicker and perhaps better for certain eye diseases. I think it's anyone guess what will happen to Visudyne sales but my bet is that sales will actually keep improving as: a) some people will choose the less invasive option; and b) some people will choose to go for combination therapy (both Visudyne and Macugen). There is also the possibility that the Visudyne/Kenalog trials might (in the future) prove even better efficacy. Time will tell...
Bullboard Posts